

## **PCMA Member Survey: The Impact of POS Rebates and POS Pharmacy DIR**

The Pharmaceutical Care Management Association (PCMA) had an independent third party conduct a survey of its members to assess the potential impact on monthly premiums for Medicare Prescription Drug Plans (PDPs) if all drug manufacturer rebates and pharmacy direct and indirect remuneration (DIR) were required to be applied at the point of sale (POS) starting next year.

Six PCMA member companies with more than 14.6 million PDP enrollees in 2018 responded to the survey, which was conducted in January 2018.

Below are the aggregate average results for these companies reported to PCMA on an enrollment-weighted basis:

- Medicare PDPs expect that 100% of PDP plans and virtually all PDP enrollees would be impacted if manufacturer rebates and pharmacy DIR were required to be applied at the point of sale (POS).
- Monthly premiums for Medicare PDPs would rise by an expected 22% in 2019 if all manufacturer rebates and all pharmacy DIR were required to be applied at POS.
  - ▶ Requiring all manufacturer rebates be applied at POS would increase monthly premiums 17%.
  - ▶ Requiring all pharmacy DIR be applied at POS would increase monthly premiums by 5%.